Digital health companies DarioHealth Corp (NASDAQ: DRIO) and OneStep announced on Monday a strategic collaboration to integrate smartphone-based, clinical-grade fall risk assessment technology into Dario's multi-condition digital health platform. The partnership aims to deliver measurable return on investment for health plans by reducing falls and improving outcomes among high-risk populations, including those with obesity and Medicare Advantage members experiencing frailty and balance issues.
Under a signed Memorandum of Understanding, with a Master Services Agreement expected shortly, Dario will incorporate OneStep's FDA-listed motion analysis technology to provide proactive fall risk identification and education. The integration will enable at-risk users to access real-time insights that support fall prevention and reduce related healthcare costs.
Falls generate more than USD50bn annually in direct medical expenses in the US, according to the Centers for Disease Control and Prevention, with Medicare and Medicaid covering around 75% of the total. The US fall management market, valued at nearly USD200m in 2024, is projected to exceed USD300m by 2033, reflecting a compound annual growth rate of more than 5%.
DarioHealth provides a multi-condition platform for chronic disease management across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
OneStep's smartphone-based gait analysis technology delivers clinical mobility insights to support fall prevention and remote patient monitoring.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies